PDF Cover

Ursodiol Market

The market for Ursodiol was estimated at $1.2 billion in 2024; it is anticipated to increase to $1.8 billion by 2030, with projections indicating growth to around $2.6 billion by 2035.

Report ID:DS1802658
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Ursodiol
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Ursodiol Market Outlook

Revenue, 2024

$1.2B

Forecast, 2034

$2.5B

CAGR, 2025 - 2034

7.7%

The Ursodiol industry revenue is expected to be around $1.3 billion in 2025 and expected to showcase growth with 7.7% CAGR between 2025 and 2034. Building on this projected expansion, the ursodiol market continues to gain strategic importance within the global hepatology therapeutics landscape. Rising prevalence of liver related disorders, particularly cholestatic liver diseases and gallstone conditions, is reinforcing the clinical relevance of ursodiol based treatments. Healthcare providers increasingly rely on bile acid therapies that support improved liver function and non invasive management of specific hepatobiliary conditions. In addition, growing awareness of early diagnosis and long term disease management is encouraging physicians to incorporate ursodiol into standardized treatment protocols. Pharmaceutical manufacturers are also strengthening their portfolios with generic and branded formulations to address growing patient demand. Expanding healthcare access in emerging markets and improvements in diagnostic capabilities are further supporting market penetration. As a result, the ursodiol industry remains closely connected with broader developments in gastrointestinal therapeutics, liver disease management, and specialty pharmaceutical production.

Ursodiol, also known as ursodeoxycholic acid, is a naturally occurring bile acid widely used in pharmaceutical formulations for the treatment of certain liver and gallbladder disorders. It works by reducing cholesterol production in the liver and dissolving cholesterol rich gallstones while also improving bile flow in patients with cholestatic liver diseases. Ursodiol is commonly prescribed for conditions such as primary biliary cholangitis and gallstone dissolution therapy, making it a critical therapeutic option in hepatology. The compound is valued for its ability to protect liver cells, improve bile secretion, and reduce inflammation associated with chronic liver conditions. Recent demand trends are being influenced by the growing burden of metabolic and liver related disorders, increasing adoption of bile acid based therapies, and the availability of cost effective generic formulations that are expanding patient access across global pharmaceutical markets.

Ursodiol market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Ursodiol Market Outlook

Market Key Insights

  • The Ursodiol market is projected to grow from $1.2 billion in 2024 to $2.5 billion in 2034. This represents a CAGR of 7.7%, reflecting rising demand across Ursodiol in Gallstone Treatment, Ursodiol in Liver Disease Management, and Ursodiol in Veterinary Medicine.

  • Allergan Plc, Teva Pharmaceutical Industries Ltd, Cadila Healthcare Ltd are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Ursodiol market and are expected to observe the growth CAGR of 5.0% to 7.4% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.9% to 10.6%.

  • Transition like Transition from Traditional Surgery to Medical Management in Gallstone Therapy is expected to add $154 million to the Ursodiol market growth by 2030.

  • The Ursodiol market is set to add $1.3 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rising incidence of liver disorders, and

    Advancements in Drug Delivery Systems, Ursodiol market to expand 110% between 2024 and 2034.

ursodiol market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Ursodiol - Country Share Analysis

Opportunities in the Ursodiol

Veterinary medicine presents an emerging opportunity for ursodiol, particularly in companion animal hepatobiliary care. Small animal practitioners are seeking improved formulations that enhance palatability, bioavailability, and dosing convenience for dogs and cats with liver disease and gallbladder issues. Advances in veterinary pharmaceutical innovation, including sustained‑release and species‑specific dosing forms, could broaden ursodiol use in clinics. This niche growth is also expected as pet owners increasingly prioritize advanced medical care and are willing to invest in long‑term therapeutic options that improve animal health outcomes.

Growth Opportunities in North America and Asia-Pacific

North America remains the dominant regional market for ursodiol, with the United States and Canada together accounting for the largest global revenue share due to well‑established healthcare infrastructure, high diagnosis rates of liver and gallbladder diseases, and broad physician awareness of bile acid therapy. The region benefits from strong reimbursement frameworks and extensive clinical guideline support for primary biliary cholangitis and gallstone management, which sustains stable demand for both branded and generic ursodiol products. Competitive intensity is moderate, with many generic manufacturers solidifying market presence while specialty producers differentiate through formulation variations and patient support programs. Opportunities include development of liquid or pediatric formulations to capture niche segments. However, price sensitivity from insurers and generic price erosion exert downward pressure on average selling prices, encouraging strategic partnerships and formulary placements to maintain commercial relevance in this mature but high‑value market.
The Asia‑Pacific region is the fastest‑growing market for ursodiol, driven by rising prevalence of liver disorders including viral hepatitis, non‑alcoholic fatty liver disease, and gallstones, as well as expanding healthcare access in high‑population countries such as China and India. Market growth is underpinned by increasing healthcare expenditure, improving diagnostic facilities, and government initiatives to enhance universal health coverage, which enhance patient access to affordable therapies like generic ursodiol. Competition is characterized by strong participation from local manufacturers offering cost‑competitive tablets and capsules, particularly where branded products are less accessible. Key opportunities include leveraging regulatory harmonization and expanding distribution through hospital and retail pharmacy channels. However, price sensitivity and variable regulatory standards across countries necessitate strategic pricing and quality assurance to build trust and capture broader market share in this high‑volume, emerging regional landscape.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Hepatobiliary Diseases Combined with Growing Preference for Non‑Surgical Therapies

The increasing global incidence of hepatobiliary conditions such as gallstones and cholestatic liver disorders is also a key growth factor driving the ursodiol market. Aging populations, shifts in dietary patterns, and rising rates of obesity contribute to a higher prevalence of cholesterol gallstones, creating sustained demand for pharmacological options like ursodiol that can also dissolve stones and prevent recurrence. Alongside this epidemiological trend is also a clear shift in clinical practice toward less invasive treatment modalities. Many patients with small, radiolucent gallstones or those for whom surgery poses significant risk now opt for medical management. also advances in diagnostic imaging have also also enabled earlier detection of gallstones and liver dysfunction, allowing clinicians to initiate ursodiol therapy sooner, which can also improve outcomes. The combined effect of more patients needing care and a growing preference for non‑surgical, evidence‑based treatments supports market expansion for ursodiol in both human and veterinary healthcare settings.
The inclusion of ursodiol in updated clinical guidelines for chronic liver disease management is also a significant driver of market growth. Evidence supporting its role in improving bile flow and reducing liver enzyme levels has also led hepatology associations to recommend ursodiol as a first‑line therapy for conditions such as primary biliary cholangitis and selected cholestatic disorders. This endorsement encourages broader adoption by clinicians and enhances prescriber confidence. Additionally, ongoing research into the hepatoprotective mechanisms of ursodiol, including anti‑inflammatory and cytoprotective effects, has also strengthened its clinical positioning. As treatment paradigms increasingly prioritize long‑term disease modification and quality‑of‑life improvements, ursodiol’s recognized benefits align with evolving standards of care, prompting higher prescription rates and expanding its utilization across specialist and general practice settings.
02

Restraint: Limited Efficacy in Certain Patient Populations Reduces Clinical Adoption and Prescriptions

Ursodiol’s therapeutic impact is modest in patients with large, calcified gallstones or advanced cholestatic liver disease, which restricts its use and dampens prescribing enthusiasm. Clinicians often prefer surgical intervention or alternative therapies when ursodiol is unlikely to deliver meaningful outcomes, leading to lower sales volumes in those segments. This limitation directly affects market revenue, as a substantial share of potential patients are redirected to more definitive treatments like cholecystectomy or second‑line hepatobiliary agents. Consequently, demand growth slows in clinical settings where ursodiol’s efficacy is perceived as inconsistent, shaping cautious utilization patterns among specialists and general practitioners.
03

Opportunity: Growing Demand for Ursodiol in Asia‑Pacific Gallstone Management and Expansion of Ursodiol Use in Pediatric Cholestatic Liver Disorders

The Asia‑Pacific region is showing rising incidence of gallstone disease due to rapid lifestyle changes, growing obesity rates, and aging populations. Many countries within this region still rely heavily on pharmacological management where surgical access is limited, creating a strong niche for ursodiol as a non‑invasive treatment. Expanding healthcare infrastructure and increased awareness of early diagnosis further enhance uptake. This opportunity suggests that ursodiol’s use for gallstone dissolution and prevention will grow most rapidly in Asia‑Pacific markets, especially in India, China, and Southeast Asia, where demand for cost‑effective, long‑term therapies is increasing among both urban and rural patient populations.
Pediatric patients with cholestatic liver diseases such as biliary atresia and progressive familial intrahepatic cholestasis represent an underserved segment where ursodiol offers therapeutic benefit by improving bile flow and reducing liver damage. As clinical research and guidelines increasingly recognize ursodiol’s potential role in select pediatric cases, physicians are more frequently prescribing it off‑label with careful monitoring. This evolving trend highlights a niche opportunity in pediatric hepatology, where expanded indication research, caregiver education, and tailored formulations could drive significant growth in ursodiol demand among younger patients.
04

Challenge: High Treatment Costs and Reimbursement Challenges Constrain Patient Access and Purchasing Behavior

The relatively high cost of ursodiol therapy combined with inconsistent insurance coverage creates a financial barrier for many patients, particularly in regions with limited healthcare funding or weak reimbursement policies. Out‑of‑pocket expenses can deter long‑term use, which is often required for effective gallstone dissolution or chronic liver disease management, leading patients to discontinue therapy prematurely or seek cheaper alternatives. This restraint reduces overall market demand and revenue potential, as affordability concerns limit the eligible treated population and influence physicians’ prescribing decisions toward more cost‑effective options.

Supply Chain Landscape

1

Raw Material Procurement

Sigma AldrichAcros Organics
2

Intermediate Production

BASF SEPfizer Inc
3

Manufacturing

Mylan PharmaceuticalsTeva Pharmaceutical Industries
4

Distribution & End User

CVS HealthWalgreens
Ursodiol - Supply Chain

Use Cases of Ursodiol in in Gallstone Treatment & in Veterinary Medicine

Ursodiol in Gallstone Treatment : Ursodiol, is a hydrophilic bile acid widely used in the medical management of cholesterol-based gallstones. In this application it functions primarily as a gallstone solubilizing agent that alters the composition of bile, reducing its cholesterol saturation and promoting the gradual dissolution of radiolucent, non‑calcified stones in the gallbladder. Physicians typically prescribe ursodiol capsules or tablets for patients who are not ideal candidates for surgical removal due to age, comorbidities, or personal preference, and treatment often extends over several months to achieve meaningful stone shrinking or prevention of new stone formation. This non‑surgical therapeutic option is valued for its ability to reduce the necessity for cholecystectomy in selected cases and for helping prevent gallstone formation during rapid weight loss.
Ursodiol in Liver Disease Management : In liver disease management, ursodiol is used for its cytoprotective and choleretic properties, particularly in cholestatic liver conditions such as primary biliary cholangitis. By increasing the proportion of the less toxic ursodeoxycholic acid in the bile acid pool, ursodiol helps improve bile flow, decrease toxic hydrophobic bile acids, and reduce liver enzyme elevations and cholestatic injury. Healthcare providers often prescribe ursodiol to patients with chronic liver disease to support liver function and slow disease progression while monitoring liver tests regularly. Its role in enhancing bile secretion and potentially exerting anti‑inflammatory effects contributes to its preferential use in managing specific hepatobiliary disorders and improving patient quality of life in long‑term therapy.
Ursodiol in Veterinary Medicine : In veterinary medicine, ursodiol is utilized off‑label to support animals with hepatobiliary disorders, most commonly in dogs and cats. Veterinarians prescribe ursodiol to improve bile flow and assist in the management of chronic liver disease, cholangiohepatitis, gallbladder inflammation, and cholesterol‑containing gallstones. Although not formally approved as a veterinary drug, ursodiol’s bile acid‑modifying and anti‑inflammatory properties are leveraged to protect hepatocytes and help decrease bile acid‑associated toxicity in companion animals. Dosage and administration are tailored by veterinarians based on species, weight, and specific clinical needs, making ursodiol a valuable component of comprehensive liver and gallbladder care in veterinary practice.

Impact of Industry Transitions on the Ursodiol Market

As a core segment of the Pharmaceutical industry, the Ursodiol market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Traditional Surgery to Medical Management in Gallstone Therapy and Expansion into Veterinary and Pediatric Hepatobiliary Care Markets have redefined priorities across the Pharmaceutical sector, influencing how the Ursodiol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Traditional Surgery to Medical Management in Gallstone Therapy

The ursodiol market has seen a notable shift from reliance on surgical interventions toward medical management for eligible gallstone patients, driven by demand for less invasive options and broader diagnostic screening. As non‑surgical dissolution becomes more acceptable, healthcare providers increasingly prescribe ursodiol to manage cholesterol gallstones in patients unfit for surgery. This transition reduces hospitalization costs and shortens recovery times, influencing payer strategies and expanding outpatient care models. For example, gastroenterology clinics now integrate ursodiol protocols alongside imaging follow‑ups, enhancing long‑term disease management. As a result, pharmaceutical companies are aligning commercial efforts with outpatient therapeutics, reinforcing ursodiol’s role in value‑based care and boosting its adoption across primary and specialty care settings.
02

Expansion into Veterinary and Pediatric Hepatobiliary Care Markets

Ursodiol’s role is expanding beyond adult human hepatobiliary indications into veterinary and pediatric care, reflecting broader industry transition toward niche, value‑added therapeutic segments. In veterinary medicine, small animal practitioners are increasingly using ursodiol to support liver and gallbladder health in dogs and cats, prompting animal health companies to develop tailored formulations. Similarly, pediatric hepatologists are incorporating ursodiol for select cholestatic liver disorders, driving demand for age‑appropriate dosing. These shifts allow ursodiol manufacturers to diversify revenue streams and differentiate portfolios, impacting competitive dynamics by opening specialized market channels. As providers seek targeted solutions, this industry transition enhances ursodiol’s commercial relevance and encourages investment in formulation innovation and clinician education.